Travere Looks Ahead To Phase III In Homocystinuria
Opportunity Bolstered By Competitor’s Recent HCU Failure
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.
